Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix demonstrates broad spectrum in vitro activity against yeasts and molds, including difficult to treat pathogens. Because of its novel mechanism of action, manogepix retains potency against many resistant strains including echinocandin-resistant Candida and azole-resistant Aspergillus. Manogepix is also active against pathogens that demonstrate intrinsic resistance to other drug classes, such as Scedosporium, Lomentospora prolificans, and Fusarium with variable activity against Mucorales. Fosmanogepix demonstrates significant in vivo efficacy in mouse and rabbit disseminated infection models due to C. albicans, C. glabrata, C. auris, C. tropicalis, Coccidioides immitis, and F. solani as well as pulmonary infection models of A. fumigatus, A. flavus, S.prolificans, S. apiospermum and Rhizopus arrhizus. Clinical trials demonstrated high oral bioavailability (>90%), enabling switching between fosmanogepix intravenous and oral formulations without compromising blood levels. Favorable drug-drug interaction, tolerability, and wide tissue distribution profiles are observed making fosmanogepix an attractive option for the treatment of invasive fungal infections. This systematic review summarizes the findings of published data on fosmanogepix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The mechanism of action of manogepix. Modified from 2019 Covel et al. [26]. Gwt1 is an enzyme which catalyzes an acyl group transfer reaction, an essential part of the GPI biosynthesis pathway. This occurs in the lumen of the endoplasmic reticulum. Gwt1 catalyzes the inositol acylation of glucosaminyl phosphatidylinositol (GlcN-PI), resulting in the formation glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), an intermediate in the biosynthesis of GPI anchors.](https://figures.cochat.ai/paper-figures/f5a1d5f19b404395b158e0a3c37f4275/fosmanogepix-a-review-of-the-first-in-class-broad-spectrum-agent-for-the-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fosmanogepix is a first in class Gwt1 fungal protein inhibitor, which is a class of proteins necessary for mannoprotein anchoring to the cell membrane and cell wall.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, with a wide tissue distribution, high oral bioavailability, and availability in both IV and oral formulations, FMGX provides drug characteristics that are favorable for treating invasive fungal infections, such as candidemia/invasive candidiasis caused by C. auris (24, 25).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“This novel mechanism provides a broad range of activity against Candida spp. including drug-resistant Candida.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Infections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Peter, O., & Menon, A. K. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700002-jlr200 · Cited by 403
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Ostrowsky, B., Greenko, J., Adams, E., Quinn, M., O’Brien, B., Chaturvedi, V., Berkow, E., Vallabhaneni, S., Forsberg, K., Chaturvedi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6901a2 · Cited by 246
Improved Outcome of Zygomycosis in Patients with Hematological Diseases?
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004) · Leukemia & Lymphoma · doi:10.1080/10428190310001653691 · Cited by 227
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Research works printed but not linked: 4
- Hata, K., Hori, T., Miyazaki, M., and Watanabe, N. (2011, January 17–20). In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, F1–1377. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
- Horii, T., Okubo, M., Miyazaki, M., Hata, K., and Watanabe, N.-A. (2010, January 12–15). In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. F1–843. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA.
- Petraitis, V., Petraitiene, R., Maung, B.B.W., Mansbach, R., Shaw, K.J., and Walsh, T.J. (2018, January 21–24). Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model. Proceedings of the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018), Madrid, Spain.
- Watanabe, N.-A., Horii, T., Miyazaki, M., and Hata, K. (2011, January 17). In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Proceedings of the F1–1378, in Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
Cited by
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“, short, stubby, abnormally branched hyphae) but not inhibition of growth as used for amphotericin B and the azoles [64, 100].”
BackgroundThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
The importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Thompson, G. R., & Young, J.-A. H. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027424 · Cited by 184
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 184
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
Mucormycosis in 2023: an update on pathogenesis and management
Alqarihi, A., Kontoyiannis, D. P., & Ibrahim, A. S. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1254919 · Cited by 180
Self-citationAdvances in Antifungal Drug Development: An Up-To-Date Mini Review
Bouz, G., & Doležal, M. (2021) · Pharmaceuticals · doi:10.3390/ph14121312 · Cited by 150
Vanreppelen, G., Wuyts, J., Dijck, P. V., & Vandecruys, P. (2023) · Journal of Fungi · doi:10.3390/jof9020171 · Cited by 128
Antifungal drug resistance: an update
Denning, D. W. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2020-002604 · Cited by 129
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“160 Results from a Phase 2 clinical trial for patients with candidemia from C. auris demonstrated safety and efficacy of fosmanogepix.”
BackgroundSubbaiah, M. A. M., Rautio, J., & Meanwell, N. A. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00957a · Cited by 115
Fungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 117
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Tortorano, A. M., Prigitano, A., Morroni, G., Brescini, L., & Barchiesi, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s274872 · Cited by 122
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1070 · Cited by 85
Invasive Pulmonary Aspergillosis
Ledoux, M., & Herbrecht, R. (2023) · Journal of Fungi · doi:10.3390/jof9020131 · Cited by 90
Fungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72
Dickwella Widanage, M. C., Gautam, I., Sarkar, D., Mentink-Vigier, F., Vermaas, J. V., Ding, S.-Y., Lipton, A. S., Fontaine, T., Latgé, J.-P., Wang, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50799-8 · Cited by 70
Wiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 67
Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives
Branda, F., Petrosillo, N., Ceccarelli, G., Giovanetti, M., VITO, A. D., Madeddu, G., Scarpa, F., & Ciccozzi, M. (2025) · Infectious Disease Reports · doi:10.3390/idr17040091 · Cited by 84
Chen, S. C.-A., Halliday, C. L., Hoenigl, M., Cornely, O. A., & Meyer, W. (2021) · Journal of Fungi · doi:10.3390/jof7010023 · Cited by 73
Brüggemann, R. J., Verheggen, R., Boerrigter, E., Stanzani, M., Verweij, P. E., Blijlevens, N. M. A., & Lewis, R. E. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00232-5 · Cited by 67
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad256 · Cited by 65
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 69
Chen, L., Zhang, L., Xie, Y., Wang, Y., Tian, X., Fang, W., Xue, X., & Wang, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115007 · Cited by 63
Invasive Aspergillosis and the Impact of Azole-resistance
Bosetti, D., & Neofytos, D. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00459-z · Cited by 63
Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review
Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 66
Hodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01623-22 · Cited by 52
“infections that have a propensity for dissemination into the brain tissue and CSF (8, 15).”
BackgroundInfluentialSelf-citationJaggi, T. K., Agarwal, R., Tiew, P. Y., Shah, A., Lydon, E., Hage, C. A., WATERER, G. W., Langelier, C., Delhaès, L., & Chotirmall, S. H. (2024) · European Respiratory Journal · doi:10.1183/13993003.00803-2024 · Cited by 63
Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 54
Samaddar, A., & Sharma, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.670731 · Cited by 54
Hoenigl, M., Sprute, R., Arastehfar, A. A., Perfect, J. R., Lass‐Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al‐Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 50
Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges
Zhang, R., Wang, Y., Wu, A., Wang, J., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115658 · Cited by 51
Our current clinical understanding of Candida biofilms: where are we two decades on?
Ramage, G., Borghi, E., Rodrigues, C. F., Kean, R., Williams, C., & Lopez-Ribot, J. L. (2023) · Apmis · doi:10.1111/apm.13310 · Cited by 50
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
Gaffney, S. M., Kelly, D., Rameli, P. M., Kelleher, E. M., & Martín‐Loeches, I. (2023) · Apmis · doi:10.1111/apm.13316 · Cited by 51
Hodges, M. R., Tawadrous, M., Cornely, O. A., Thompson, G. R., Slavin, M. A., Maertens, J. A., Dadwal, S., Rahav, G., Hazel, S., Almas, M., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf185 · Cited by 51
Update on therapeutic approaches for invasive fungal infections in adults
Boutin, C.-A., & Luong, M. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231224980 · Cited by 54
Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health
de Oliveira, H. C., Bezerra, B. T., & Rodrigues, M. L. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00055 · Cited by 46
Fungal cell wall biogenesis: structural complexity, regulation and inhibition
Gow, N. A. R. (2025) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2025.103991 · Cited by 47
Invasive Aspergillosis in the Intensive Care Unit
Townsend, L., & Martín‐Loeches, I. (2022) · Diagnostics · doi:10.3390/diagnostics12112712 · Cited by 43
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective
Ordaya, E. E., Clement, J., & Vergidis, P. I. (2023) · Mycopathologia · doi:10.1007/s11046-023-00759-5 · Cited by 44
Critical appraisal beyond clinical guidelines for intraabdominal candidiasis
Maseda, E., Martín‐Loeches, I., Zaragoza, R., Pemán, J., Fortün, J., Grau, S., Aguilar, G., Varela, M., Borges-Sa, M., Giménez, M.-J., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04673-6 · Cited by 40
New antifungal strategies and drug development against WHO critical priority fungal pathogens
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1662442 · Cited by 53
Maphanga, T. G., Mpembe, R. S., Naicker, S. D., Govender, N. P., & GERMS-SA, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01717-21 · Cited by 42
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician
Lamoth, F. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s375625 · Cited by 43
The antifungal pipeline for invasive fungal diseases: what does the future hold?
Neoh, C. F., Jeong, W., Kong, D. C. M., & Slavin, M. A. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2203383 · Cited by 45
Latest Research Trends in Agrochemical Fungicides: Any Learnings for Pharmaceutical Antifungals?
Lamberth, C. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00113 · Cited by 47
Madhavan, Y., Sai, K. V., Shanmugam, D. K., Aashabharathi, M., Devi, G. K., Mohanta, Y. K., Venugopal, D. C., Mohanta, T. K., Sharma, N., & Saravanan, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133620 · Cited by 37
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Gutierrez-Perez, C., & Cramer, R. A. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00093-4 · Cited by 43
Pfaller, M. A., Huband, M. D., Rhomberg, P. R., Bien, P. A., & Castanheira, M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-22 · Cited by 37
Niño‐Vega, G. A., Padró-Villegas, L., & López-Romero, E. (2024) · Journal of Fungi · doi:10.3390/jof10120871 · Cited by 40
John, L. L. H., Thomson, D. D., Bicanic, T. A., Hoenigl, M., Brown, A. J. P., Harrison, T. S., & Bignell, E. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-22 · Cited by 37
Allergic bronchopulmonary aspergillosis: A multidisciplinary review
Roboubi, A., Audousset, C., Fréalle, É., Brun, A., Laurent, F., Vitte, J., Mortuaire, G., Lefèvre, G., Cadranel, J. L., & Chenivesse, C. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101392 · Cited by 34
Antifungal Susceptibility Testing and Identification
Kidd, S. E., Crawford, L. C., & Halliday, C. L. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.004 · Cited by 32
Review of current and future therapeutics in ABPA
Lewington-Gower, E., Chan, L. T., & Shah, A. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211047003 · Cited by 31
Review of treatment options for a multidrug-resistant fungus: Candida auris
Wang, S., Pan, J., Gu, L., Wang, W., Wei, B., Zhang, H., Chen, J., & Wang, H. (2023) · Medical Mycology · doi:10.1093/mmy/myad127 · Cited by 34
Uniqueness of Candida auris cell wall in morphogenesis, virulence, resistance, and immune evasion
Dakalbab, S., Hamdy, R., Holigová, P., Abuzaid, E. J., Abu-Qiyas, A., Lashine, Y., Mohammad, M. G., & Soliman, S. S. M. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127797 · Cited by 31
Fosmanogepix Therapy of Disseminated Fusarium Infection
Winston, D. J., Young, P. A., Schlamm, H. T., & Schiller, G. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad309 · Cited by 30
Susan, V., Lang, M., Sabou, M., & Bourel‐Bonnet, L. (2025) · Pharmaceuticals · doi:10.3390/ph18081220 · Cited by 30
Xu, H., Mou, Y., Guo, M., Zhang, R., Yan, Z.-Z., An, R., Wang, X., Su, X., Hou, Z., & Guo, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114707 · Cited by 28
Coccidioidomycosis: a growing global concern
Donovan, F., Fernández, O. M., Bains, G., & DiPompo, L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf002 · Cited by 29
Small molecules for combating multidrug-resistant superbug Candida auris infections
Tu, J., Liu, N., Huang, Y., Yang, W., & Sheng, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.001 · Cited by 29
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Treviño‐Rangel, R. D. J., González, G. M., Montoya, A. M., Rojas, O. C., Elizondo-Zertuche, M., & Álvarez‐Villalobos, N. A. (2022) · Journal of Fungi · doi:10.3390/jof8111144 · Cited by 29
Pfaller, M. A., Huband, M. D., Bien, P. A., Carvalhaes, C. G., Klauer, A. L., & Castanheira, M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01132-23 · Cited by 27
The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies
Zobi, C., & Algül, Ö. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70045 · Cited by 26
Recent Advances in the Development of Antifungal Agents: Beyond Azoles, Polyenes, and Echinocandins
Saini, V., Safwan, S. M., Mehta, D., Das, E. E., & Bajaj, A. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00828 · Cited by 25
Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections
Liu, N., Tu, J., Huang, Y., Yang, W., Wang, Q., Li, Z., & Sheng, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114819 · Cited by 26
Advances in anti-fungal therapies
WATERER, G. W. (2021) · Mycopathologia · doi:10.1007/s11046-021-00560-2 · Cited by 21
Novel avenues for identification of new antifungal drugs and current challenges
Jampílek, J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2097659 · Cited by 22
Antifungal resistance, combinations and pipeline: oh my!
Stover, K. R., Hawkins, B. K., Keck, J. M., Barber, K. E., & Cretella, D. A. (2023) · Drugs in Context · doi:10.7573/dic.2023-7-1 · Cited by 22
Lee, A., Wang, N., Carter, C. L., Zimmerman, M., Dartois, V. A., Shaw, K. J., Perlin, D. S., & Zhao, Y. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-20 · Cited by 21
Self-citationAn overview of current and emerging antifungal pharmacotherapy for invasive fungal infections
Mueller, S. W., Kedzior, S. K., Miller, M. A., Reynolds, P., Kiser, T. H., Kršák, M., & Molina, K. C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892075 · Cited by 22
Du, W., Wang, Q., & Zhao, M. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1641373 · Cited by 20
Challenges in the diagnosis and treatment of candidemia due to multidrug-resistant Candida auris
Giacobbe, D. R., Mikulska, M., Vena, A., Pilato, V. D., Magnasco, L., Marchese, A. E., & Bassetti, M. (2023) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2023.1061150 · Cited by 20
Cornely, O. A., Ostermann, H., Koehler, P. A., Teschner, D., Limburg, E., Kramer, W. G., Barbat, S. H., Tawadrous, M., & Hodges, M. R. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad269 · Cited by 21
What do We Know about Cryptic Aspergillosis?
Geremia, N., Giovagnorio, F., Colpani, A., VITO, A. D., Caruana, G., Meloni, M. C., Madeddu, G., Panese, S., & Parisi, S. G. (2024) · Microorganisms · doi:10.3390/microorganisms12050886 · Cited by 21
Espinel‐Ingroff, A., & Wiederhold, N. P. (2024) · Journal of Fungi · doi:10.3390/jof10050362 · Cited by 19
Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review
Echeverría-Esnal, D., Martín‐Ontiyuelo, C., Navarrete-Rouco, M. E., Barceló‐Vidal, J., Conde‐Estévez, D., Carballo, N., de Antonio-Cuscó, M., Ferrández, O., Horcajada, J. P., & Grau, S. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1962292 · Cited by 21
Ettadili, H., & Vural, C. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-01239-0 · Cited by 20
Discovery of 1,2,3-selenadiazole analogues as antifungal agents using a scaffold hopping approach
Xu, H., Cao, C., Wang, X., Guo, M., Yan, Z.-Z., An, R., Zhang, R., Dong, E.-H., Mou, Y., Hou, Z., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105182 · Cited by 19
Current Trends in Clinical Trials of Prodrugs
Boreski, D., Schmid, V. F., Bosquesi, P. L., dos Santos, J. L., Scarim, C. B., Reshetnikov, V., & Chin, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020210 · Cited by 18
Zhou, Y., & Reynolds, T. B. (2024) · Journal of Fungi · doi:10.3390/jof10030171 · Cited by 19
Hsu, A. J., Hanisch, B. R., Fisher, B. T., & Huppler, A. R. (2024) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad115 · Cited by 17
Goggin, K. P., Londeree, J., Freeman, A. F., Garro, R., & George, R. P. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad285 · Cited by 16
Current Landscape of Coccidioidomycosis
Boro, R., Iyer, P. C., & Walczak, M. A. A. (2022) · Journal of Fungi · doi:10.3390/jof8040413 · Cited by 18
Novel Approaches in the Management of Mucormycosis
Lamoth, F. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00463-3 · Cited by 20
Candida auris : host interactions, antifungal drug resistance, and diagnostics
Chowdhary, A., Lionakis, M. S., & Chauhan, N. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00187-22 · Cited by 22
An Update on the Global Treatment of Invasive Fungal Infections
Munzen, M. E., Garcia, A. D. G., & Martinez, L. R. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0269 · Cited by 16
Mucormycosis: A Rare disease to Notifiable Disease
Panda, S., Sahu, M. C., Turuk, J., & Pati, S. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01315-z · Cited by 17
Vij, R., Hube, B., & Brunke, S. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.02.003 · Cited by 16
From the Ground to the Clinic: The Evolution and Adaptation of Fungi
Corrêa-Junior, D., Zamith‐Miranda, D., Frasés, S., & Nosanchuk, J. D. (2025) · Journal of Fungi · doi:10.3390/jof12010008 · Cited by 16
Fungal Infection in Lung Transplantation
Kennedy, C. C., Pennington, K. M., Beam, E. N., & Razonable, R. R. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1729173 · Cited by 16
Overcoming Global Antifungal Challenges: Medical and Agricultural Aspects
Galgóczy, L. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00103 · Cited by 17
Bing, J., Li, S., Ji, L., Du, H., Shamoon, N. M., Nobile, C. J., & Huang, G. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00394-25 · Cited by 15
Design, synthesis, evaluation and optimization of novel azole analogues as potent antifungal agents
Zhang, J., Wang, Z., Gai, C., Yang, F., Yun, X., Jiang, B., Zou, Y., Meng, Q., Zhao, Q., & Chai, X. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117543 · Cited by 13
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis
Giamberardino, C. D., Schell, W. A., Tenor, J. L., Toffaletti, D. L., Palmucci, J. R., Marius, C., Boua, J.-V. K., Soltow, Q. A., Mansbach, R. S., Moseley, M. A., et al. (2022) · mBio · doi:10.1128/mbio.02347-22 · Cited by 15
Self-citationCalcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens
Liston, S. D., Whitesell, L., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2022) · Journal of Fungi · doi:10.3390/jof8101102 · Cited by 12
Self-citation
Metadata
- Authors
- Shaw, K. J., & Ibrahim, A. S.
- Affiliations
- Hearts Consulting Group, LLC, Poway, CA 92064, USA
- University of California, Los Angeles (US)
- Corresponding author
- Shaw, Karen Joy
- Ibrahim, Ashraf S.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-10-22
- Volume
- 6
- Issue
- 4
- Pages
- 239
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC7711534
- OpenAlex
- W3093555016
- Cited by
- 229
- References
- 64
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 36 · 2023: 47 · 2022: 30 · 2021: 25
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- fosmanogepix, manogepix, invasive fungal infections, antifungal drug development, Candida, Aspergillus, echinocandin resistance, azole resistance, Scedosporium, Lomentospora prolificans, Fusarium, Mucorales, oral bioavailability, drug-drug interactions, drug tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.